www.finanznachrichten.de · · DE
68737788 bioinvent international bioinvent s tnfr2 antibody bi 1808 delivers meaningful responses and immune activation as single agent and in combination wit 200
News Analysis — AI Analysis
Original analysis generated by News Analysis. This is our own commentary on the story, not the publisher's article text.
BioInvent presented clinical data from its Phase 2a trial for BI-1808, an anti-TNFR2 antibody, at the EHA 2026 Congress. The results showed that BI-1808 achieved a 40% objective response rate (ORR) as monotherapy and a 50% ORR when combined with KEYTRUDA (pembrolizumab). Furthermore, the drug demonstrated strong immune activation by depleting regulatory T cells (Tregs), suggesting potential for advanced CTCL treatment.
Key points
- BI-1808 is an anti-TNFR2 monoclonal antibody being evaluated for advanced Cutaneous T-cell Lymphoma (CTCL).
- As monotherapy, BI-1808 achieved a 40% ORR and a 93% disease control rate (DCR), including a complete response sustained over two years.
- In combination with KEYTRUDA, the drug showed a 50% ORR in heavily pretreated patients.
- The mechanism of action involves depleting immunosuppressive Tregs and enhancing anti-tumor immunity by activating CD8+ T cells.
- BI-1808 has received several designations, including FDA Fast Track and Orphan Drug status for CTCL.
Claims assessed
- VerifiableBI-1808 monotherapy achieved a 40% objective response rate (ORR) in advanced CTCL.
- VerifiableThe combination of BI-1808 with KEYTRUDA resulted in a 50% ORR in patients who had received multiple prior lines of therapy.
- VerifiableBI-1808's mechanism involves depleting Tregs and activating CD8+ T cells, which is measurable through markers like IL-12 and CXCL11 induction.
- VerifiableThe drug has received FDA Fast Track Designation for relapsed or refractory MF and SS, and Orphan Drug Designation for T-cell lymphoma.
Missing context
The article does not specify the total number of patients in the Phase 2a cohort or provide detailed survival data beyond mentioning a complete response sustained at two years. It also lacks comparative efficacy data against current standard-of-care treatments.
Topic context
Related topics
The full article is on the original publisher site.
Related stories
finanznachrichten.de
68738324 curium group peptidream and pdradiopharma announce completion of patient dosing in clinical trial of 64cu psma i t for prostate cancer in japan 399
finance.yahoo.com
Broader Market Settles Lower Chip
zerohedge.com
Flesh Eating Parasite Threatening Our Food Supply What You Can Do Stay Healthy
links.org.au
Claudio Katz Argentine Left Must Aim Govern Strategy Power
texarkanagazette.com